Yuhong Lu, PhD, MD
Associate Research Scientist in Therapeutic RadiologyCards
About
Research
Publications
2025
Hypoxia Induces Immunosuppression by Silencing STING in Cancer.
Lu Y, Yurkevicz A, Liu Y, Glazer P. Hypoxia Induces Immunosuppression by Silencing STING in Cancer. Cancer Research 2025, 85: 4664-4680. PMID: 40939188, PMCID: PMC12498107, DOI: 10.1158/0008-5472.can-24-2038.Peer-Reviewed Original ResearchThis study shows that tumor hypoxia silences the STING pathway, impairing immune response in cancer, and suggests targeting KDM1A to restore STING and enhance cancer therapy.
2016
Regulation of DNA Repair by Hypoxia
Lu Y, Glazer P. Regulation of DNA Repair by Hypoxia. 2016, 169-188. DOI: 10.1142/9789813147324_0007.Peer-Reviewed Original Research
2011
Hypoxia-Induced Epigenetic Regulation and Silencing of the BRCA1 Promoter
Lu Y, Chu A, Turker MS, Glazer PM. Hypoxia-Induced Epigenetic Regulation and Silencing of the BRCA1 Promoter. Molecular And Cellular Biology 2011, 31: 3339-3350. PMID: 21670155, PMCID: PMC3147797, DOI: 10.1128/mcb.01121-10.Peer-Reviewed Original ResearchConceptsBRCA1 promoterH3K9 acetylationLysine-specific histone demethylase LSD1BRCA1 tumor suppressorShort-term repressionDNA methylation inhibitorHistone demethylase LSD1Hypoxic stressTreatment of cellsH3K9 methylationRepressive modificationsGenome instabilityHistone modificationsEpigenetic regulationEpigenetic modificationsDemethylase LSD1Methylation inhibitorTranscriptional levelHistone deacetylase inhibitorsTumor suppressorPromoterHPRT geneMethylationSporadic cancersBRCA1 expression
2010
Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130
Hegan DC, Lu Y, Stachelek GC, Crosby ME, Bindra RS, Glazer PM. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proceedings Of The National Academy Of Sciences Of The United States Of America 2010, 107: 2201-2206. PMID: 20133863, PMCID: PMC2836641, DOI: 10.1073/pnas.0904783107.Peer-Reviewed Original ResearchMeSH KeywordsCell Line, TumorColonic NeoplasmsCrk-Associated Substrate ProteinDNA RepairDown-RegulationE2F4 Transcription FactorEnzyme InhibitorsGenes, BRCA1HumansPhenanthrenesPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesPromoter Regions, GeneticRad51 RecombinaseRadiation-Sensitizing AgentsRNA, Small InterferingConceptsHomology-dependent repairBase excision repair factorsExcision repair factorsPARP inhibitionRole of PARPPARP inhibitorsRepair factorsExpression of BRCA1DNA repairDNA breaksHypoxic cancer cellsRAD51SiRNA knockdownDNA damagePARP-1P130 expressionCancer therapyP130Cancer cellsPARPRad51 promoterHPV E7BRCA1E7 expressionSiRNAs
2004
Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells.
Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. International Journal Of Cancer. Journal International Du Cancer 2004, 108: 334-41. PMID: 14648698, DOI: 10.1002/ijc.11445.Peer-Reviewed Original ResearchOverexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells.
Lu Y, Zi X, Zhao Y, Pollak M. Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells. Biochemical And Biophysical Research Communications 2004, 313: 709-15. PMID: 14697248.Peer-Reviewed Original Research
2002
Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.
Camirand A, Lu Y, Pollak M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Medical Science Monitor : International Medical Journal Of Experimental And Clinical Research 2002, 8: BR521-6. PMID: 12503030.Peer-Reviewed Original Research
2001
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).
Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). Journal Of The National Cancer Institute 2001, 93: 1852-7. PMID: 11752009.Peer-Reviewed Original Research
Get In Touch
Contacts
Email